AbbVie Receives European Commission Approval of ELAHERE® …
Nov 18, 2024 · ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer; ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy
Corcept Announces Results From Phase 2 Study of Dazucorilant in ...
Dec 14, 2024 · REDWOOD CITY, CA, USA I December 11, 2024 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo ...
PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) …
Jan 8, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
BlueRock Therapeutics advances investigational cell therapy ...
Jan 13, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial ...
Dec 20, 2024 · Topline Clinical Data Demonstrates Activity of SOR102 Across Multiple Clinical Endpoints Supporting Advancement to Phase 2 Development SALT LAKE CITY, UT, USA I December 19, 2024 I Sorriso Pharmaceuticals, a biopharmaceutical company developing novel orally dosed antibodies for immune-mediated ...
Takeda Provides an Update on Alofisel® (darvadstrocel)
Dec 16, 2024 · OSAKA, Japan and CAMBRIDGE, MA, USA I December 13, 2024 I Takeda (TSE:4502/NYSE:TAK) today announced that the company is working with the European Medicines Agency (EMA) to voluntarily withdraw the marketing authorization of Alofisel® (darvadstrocel), a treatment for complex perianal fistulas in patients with Crohn’s disease, in the European Union (EU).
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 31, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Positive Scientific Advice from the U.S. FDA for Planned Phase II …
KIEL, Germany I January 08, 2025 I tiakis Biotech AG, a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that the Company has received positive scientific advice from the U.S. FDA on a planned Phase II trial for the treatment of Pulmonary Arterial Hypertension (PAH).
European Commission approves RYBREVANT® (amivantamab) in …
Dec 30, 2024 · This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC 1. In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced the risk of disease progression or death by 30 percent versus osimertinib monotherapy 1. BEERSE, Belgium I Decemer 30, 2024 I Janssen-Cilag ...